What are the highlights of the Admilral (Fluorouracil) parent trial use?

From the Guidelines

The AdmilParent trial is not directly mentioned in the provided evidence, however, the discussion around adjuvant chemotherapy for stage II colon cancer highlights the importance of considering the potential benefits and risks of treatment, with a focus on individual patient and tumor factors. When considering adjuvant chemotherapy for stage II colon cancer, it is essential to discuss the potential benefits and risks with the patient, taking into account their individual preferences and values 1. The patient's perceptions of risks and benefits, as well as their understanding of the potential incremental improvement in cure rate with chemotherapy, should be carefully considered 1. Key points to discuss include:

• The potential incremental improvement in cure rate with chemotherapy, which is limited, with clinical trials suggesting a 2-4% improvement in 5-year survival rates 1
• The potential risks of chemotherapy, including toxicity and the risk of treatment-related death, which is less than 1% 1
• The importance of considering individual patient and tumor factors, such as tumor characteristics and comorbidities, when making treatment decisions 1
• The availability of tools, such as numeracy programs, to help patients and physicians analyze individual patient risk and make informed decisions 1 In terms of specific treatment recommendations, the NCCN guidelines for colon cancer suggest that adjuvant chemotherapy may be considered for patients with stage II colon cancer, particularly those with high-risk features, such as T4 lesions or inadequate lymph node sampling 1. However, the decision to use adjuvant chemotherapy should be made on a case-by-case basis, taking into account the individual patient's preferences and values, as well as their overall health and tumor characteristics. It is essential to weigh the potential benefits of treatment against the potential risks and to consider the patient's quality of life and overall prognosis when making treatment decisions. Ultimately, the goal of treatment should be to improve the patient's overall survival and quality of life, while minimizing the risks and side effects of treatment.

From the Research

Admilparent Trial Use Highlights

• The admilparent trial, also known as the Admilparant trial, was a phase 2 randomized clinical trial that assessed the efficacy and safety of admilparant in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) 2.
• The trial included parallel cohorts of patients with IPF and PPF who received 30 mg or 60 mg of admilparant, or a placebo, twice daily for 26 weeks.
• The results showed that 60-mg admilparant slowed lung function decline in both IPF and PPF patients, with treatment differences between 60-mg admilparant and placebo of 1.4% for IPF and 3.2% for PPF.
• The trial also found that admilparant was safe and well-tolerated, with similar frequencies of diarrhea and transient blood pressure reductions compared to placebo.
• The study suggests that admilparant may be a potential treatment option for patients with IPF and PPF, and further evaluation in phase 3 trials is warranted 2.

Key Findings

• The admilparent trial demonstrated the efficacy and safety of admilparant in patients with IPF and PPF.
• The trial results support the use of admilparant as a potential treatment option for these patients.
• Further research is needed to fully understand the benefits and risks of admilparant in these patient populations.

Study Limitations

• The trial was a phase 2 study, and larger, longer-term studies are needed to confirm the findings.
• The trial had a limited sample size, and the results may not be generalizable to all patients with IPF and PPF.
• The study did not compare admilparant to other treatments for IPF and PPF, and further research is needed to determine its place in therapy 2.